The CC is less than two weeks away so a lot can change quickly. On ngio alone, there’s a lot in today’s press release to flesh out once the company is ready. The merger tidbit alone is very interesting. I’m curious if that’s a publicly traded company, besides the statement that they have phase II drugs or vaccines. Plus the other acquisitions- there’s a lot to bring future value so while it’s frustrating at times there’s certainly a bigger picture unfolding.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links